natgillin/translations-raw huggingface dataset:
Vimpat 600 mg viste sig også at være effektiv i kontrollerede forsøg med tillægsbehandling, selvom effekten var den samme som ved 400 mg/dag og patienterne ofte tålte denne dosis dårligere på grund af bivirkninger relateret til centralnervesystemet og mave- tarm-kanalen.
Vimpat 600 mg/day was also shown to be effective in controlled adjunctive therapy trials, although the efficacy was similar to 400 mg/day and patients were less likely to tolerate this dose because of CNS- and gastrointestinal-related adverse reactions.
Vimpat anvendes til at behandle partielle anfald (epileptiske krampeanfald, der udspringer fra en bestemt del af hjernen) som tillæg til andre antiepileptiske lægemidler hos epilepsipatienter i alderen 16 år og opefter.
Vimpat is used to treat partial-onset seizures (epileptic fits starting from one specific part of the brain) as an add-on to other antiepileptic medicines in patients with epilepsy aged 16 years and older.
Vimpat bruges som supplement til anden antiepileptisk medicin.
Vimpat is used in addition to other antiepileptic medicines.
Vimpat bruges til den epilepsiform, hvor anfaldene til at begynde med kun rammer den ene side af hjernen, men som efterfølgende kan omfatte større områder i begge sider af hjernen (partielle anfald med eller uden sekundær generalisering).
Vimpat is used for the epilepsy form in which the fits initially affect only one side of the brain, but could thereafter extend to larger areas on both sides of the brain (partial onset seizure with or without secondary generalisation).
Vimpat bør ikke anvendes til børn og unge under 16 år.
Vimpat is not recommended for children and adolescents aged under 16 years.
Vimpat er et lægemiddel, der indeholder det aktive stof lacosamid.
Vimpat is a medicine containing the active substance lacosamide.
Vimpat er indiceret som tillægsbehandling af fokale anfald med eller uden sekundær generalisering hos voksne og unge (16-18 år) med epilepsi.
Vimpat is indicated as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adult and adolescent (16-18 years) patients with epilepsy.
Vimpat er ordineret til Dem af Deres læge for at reducere antallet af anfald.
Vimpat has been given to you by your doctor to reduce the number of fits.
Vimpat fås i flasker med 200 ml og 465 ml.
Vimpat is available in bottles of 200 ml and 465 ml.
Vimpat fås i pakninger med 14, 56 og 56 x 1 filmovertrukne tabletter samt i multipakninger indeholdende 3 pakninger á 56 tabletter.
Vimpat is available in packs of 14, 56 and 56 x 1 film-coated tablets and in multipacks comprising 3 cartons, each containing 56 tablets.
Vimpat gives til Dem som infusion i en blodåre (intravenøst) af en læge eller sygeplejerske.
Vimpat is administered as an infusion into a vein (intravenously) by a healthcare professional.
Vimpat indeholder natrium
Important information about some of the ingredients of Vimpat
Vimpat indeholder sorbitol, natrium, natriummethylparahydroxybenzoat og aspartam
Important information about some of the ingredients of Vimpat
Vimpat infusionsvæske, opløsning kan indgives intravenøst uden yderligere fortynding eller kan fortyndes med natriunchlorid 9 mg/ml (0,9 %) injektionsvæske, opløsning, glucose 50 mg/ml (5 %) injektionsvæske, opløsning eller Ringer’s laktat injektionsvæske, opløsning.
Vimpat solution for infusion can be administered intravenously without further dilution or can be diluted with sodium chloride 9 mg/ml (0.9%) solution for injection, glucose 50 mg/ml (5%) solution for injection or lactated Ringer’s solution for injection.
Vimpat kan medføre svimmelhed eller sløret syn.
Vimpat may cause dizziness or blurred vision.
Vimpat kan medføre svimmelhed, der vil kunne øge risikoen for tilskadekomst eller fald.
Vimpat may cause dizziness, which could increase the risk of accidental injury or a fall.
Vimpat må ikke anvendes til patienter, der er overfølsomme (allergiske) over for lacosamid eller andre af indholdsstofferne, eller som har en AV-blok af 2. eller 3. grad (en form for forstyrrelse af hjerterytmen).
Vimpat must not be used in people who are hypersensitive (allergic) to lacosamide or any of the other ingredients, or who have second or third degree AV block (a type of heart rhythm disorder).
Vimpat skal gives to gange daglig, én gang om morgenen og én gang om aftenen, på omtrent samme tidspunkt hver dag.
Vimpat must be administered twice a day, once in the morning and once in the evening, at about the same time each day.
Vimpat skal tages to gange daglig, én gang om morgenen og én gang om aftenen, på omtrent samme tidspunkt hver dag.
Vimpat must be taken twice a day, once in the morning and once in the evening, at about the same time each day.
Vimpat som infusion kan anvendes til at indlede behandlingen.
Vimpat infusion can be used to initiate treatment.
Vimpat taget gennem munden blev sammenlignet med placebo (uvirksom behandling) i tre hovedundersøgelser med i alt 1 308 patienter.
Vimpat taken by mouth has been compared with placebo (a dummy treatment) in three main studies involving a total of 1,308 patients.
Vimpat-behandlingsstartpakken indeholder 4 forskellige pakninger (én til hver tabletstyrke) med 14 tabletter i hver til de første 2-4 ugers behandling afhængig af virkningen og bivirkningsprofilen hos den enkelte patient.
Vimpat treatment initiation pack contains 4 different packages (one for each tablet strength) with 14 tablets each, for the first 2 to 4 weeks of therapy depending on the patient´s response and tolerability.
Vimpat-infusionsvæske, opløsning er fysisk kompatibelt og kemisk stabilt i mindst 24 timer, når den blandes med følgende fortyndere og opbevares i glas eller PVC-poser ved temperaturer op til 25 °C. Fortyndere:
Vimpat solution for infusion was found to be physically compatible and chemically stable when mixed with the following diluents for at least 24 hours and stored in glass or PVC bags at temperatures up to 25°C.
Vimpat-infusionsvæske, opløsning kan gives uden yderligere fortynding eller kan fortyndes med følgende opløsninger: natriumchlorid 9 mg/ml (0,9%), glucose 50 mg/ml (5%) eller Ringer’s laktat opløsning.
Vimpat solution for infusion can be administered without further dilution, or may be diluted with the following solutions: sodium chloride 9 mg/ml (0.9%), glucose 50 mg/ml (5%) or lactated Ringer’s solution.
Vimpat-syrup 10 mg/ml er en lidt tyktflydende, klar opløsning med svag gulbrun farve.
Vimpat 10 mg/ml syrup is a slightly viscous clear, colourless to yellow-brown liquid.
Vimpat-syrup indeholder natriummethylparahydroxybenzoat (E219), der kan give allergiske reaktioner (kan optræde efter behandlingen).
Vimpat syrup contains sodium methyl parahydroxybenzoate (E219), which may cause allergic reactions (possibly delayed). ).
Vimpat-syrup indeholder: sorbitol (en sukkerart).
Vimpat syrup contains: sorbitol (a type of sugar).
Vimpat-tabletter og oral syrup er bioækvivalente.
Vimpat tablets and syrup are bioequivalent.
Vimpatbehandlingen starter almindeligvis med en dosis på 100 mg pr. dag - halvdelen (50 mg) gives om morgenen og halvdelen (50 mg) gives om aftenen.
The treatment with Vimpat starts usually with a dose of 100 mg daily given half (50 mg) in the morning and half (50 mg) in the evening.
vin: 13 dage; får: 16 dage
pigs: 13 days; sheep: 16 days
vincaalkaloider bør derfor undgås, medmindre fordelen for patienten opvejer risikoen.
Therefore, concomitant use of posaconazole and vinca alkaloids should be avoided unless the benefit to the patient outweighs the risk.
Vincamin i.v.
Vincamine i.v.
Vincristin (anvendes til at behandle visse former for kræft), da anvendelse af vincristin sammen med asparaginase kan øge risikoen for visse bivirkninger.
Vincristine (used to treat certain types of cancer) since the simultaneous use of vincristine and asparaginase may increase the risk of certain side effects.
Vincristin skal derfor gives rettidigt inden administration af Oncaspar for minimere toksiciteten.
Therefore, vincristine should be given in a timely manner before administration of Oncaspar in order to minimise toxicity.
Vincristin, vinblastin og andre vinca alkaloider (anvendt i cancerbehandling)
Vincristine, vinblastine and other vinca alkaloids (used to treat cancer)
vincristin, vinblastin og andre “vinkaalkaloider” (anvendes til behandling af kræft)
vincristine, vinblastine and other “vinca alkaloids” (used to treat cancer)
vincristin, vinblastin og andre ”vinkaalkaloider” (anvendes til behandling af kræft)
vincristine, vinblastine and other “vinca alkaloids” (used to treat cancer)
vincristin, vinblastin, der bruges til behandling af kræft mycophenolatmofetil (MMF), der bruges til transplantationspatienter
vincristine, vinblastine, used for cancer, mycophenolate mofetil (MMF), used in transplant patients,
vind af muskelmasse, ledsmerter, muskelsmerter
muscle atrophy (muscle shrinkage), arthralgia (joint pain), myalgia (aching muscles)
Vindesin 3 mg/m2 i.v., dag 1;
Vindesine 3 mg/m2 i.v., day 1;
Vindesin 3 mg/m² i.v., dag 1;
Vindesine 3 mg/m2 i.v., day 1;
VINDUE
cinal cinal
vindue
Dose Window
Vindue for injektion sstatus
Injection Status Window
Vindue Indvendig kanyledæksel Cosentyx SensoReady-pen, vist med hætten fjernet.
Cosentyx SensoReady pen shown with the cap removed.
Vindue Nålebeskytter
"Push-On Needle"
Vindue Nålebeskytter
Device body
vinduet
window
Vinduet begynder at blive gult.
The window will start to turn yellow.
Vinflunin elimineres efter et multi-eksponentielt koncentrationshenfald med en terminal halveringstid (t1/2) tæt på 40 timer.
Vinflunine is eliminated following a multi-exponential concentration decay, with a terminal half-life (t1/2) close to 40 h.
Vinflunin er ikke blevet evalueret hos patienter med svært nedsat leverfunktion (Child-Pugh grad C) eller hos patienter med protrombintid < 50 % NV eller med bilirubin > 5ULN eller med isolerede aminotransferaser > 2,5×ULN ( ≥ 5×ULN kun i tilfælde af levermetastaser) med GGT > 15ULN.
Vinflunine has not been evaluated in patients with severe hepatic impairment (Child-Pugh grade C), or in patients with a prothrombin time < 50%NV or with bilirubin > 5xULN or with isolated transaminases > 2.5xULN ( ≥ 5xULN only in case of liver metastases) or with GGT > 15xULN.
Vinflunin er moderat bundet til humane plasmaproteiner (67,21,1%) med et forhold mellem plasmaet og helblod-koncentrationerne på 0,800,12.
Vinflunine is moderately bound to human plasma proteins (67.2±1.1%) with a ratio between plasma and whole blood concentrations of 0.800.12.
Vinflunins farmakokinetik var uændret hos disse patienter, dog er der fastlagt følgende dosisanbefalinger baseret på ændringer i hepatiske biologiske parametre (gammaglutamyltransferaser (GGT), aminotransferaser, bilirubin) som følge af indgift af vinflunin:
Vinflunine pharmacokinetics was not modified in those patients, however based on hepatic biologic parameter modifications following vinflunine administration (gamma glutamyl transferases (GGT), transaminases, bilirubin), the dose recommendations are as follows:
Vinkaalkaloider (f.eks. vincristin og vinblastin) (medicin mod cancer)
Vinca alkaloids (e.g., vincristine and vinblastine) (used in treating cancer)
Vinkaalkaloider (f.eks. vincristin og vinblastin) [CYP3A4 substrate]
Vinca Alkaloids (e.g., vincristine and vinblastine)
Vinkistin 1,3 mg/m2 i.v., dag 1, 8, 15, 21; Prednisolon 60 mg/m2/dag oral
Vincristine 1.3 mg/m2 i.v., days 1, 8, 15, 21; Prednisolone 60 mg/m2/day oral
Vinkristin 1,3 mg/m² i.v., dag 1, 8, 15, 21; Prednisolon 60 mg/m²/dag oral
Vincristine 1.3 mg/m2 i.v., days 1, 8, 15, 21; Prednisolone 60 mg/m2/day oral
Vinkristin 2 mg i.v., dag 4, 11;
Vincristine 2 mg i.v., days 4, 11;
Vinsyre (E334) Mannitol (E421) Saltsyre (E507) Natriumhydroxid
Tartaric acid (E334) Mannitol (E421) Hydrochloric acid(E507) Sodium hydroxide
Vinsyre (E334), mannitol (E421), saltsyre (E507), natriumhydroxid.
tartaric acid (E334), mannitol (E421), hydrochloric acid (E507), sodium hydroxide.
Vinsyre Ethylcellulose Hypromellose
Tartaric acid Ethylcellulose Hypromellose
Violette eller rødbrune pletter under huden
Purple or red brown spots visible through the skin (thrombocytopenic purpura)
Vip hætteglasset til en vinkel på ca.
Tilt the vial to an angle of approx.
Vip igen pennen langsomt og forsigtigt fra side til side 5 gange for at efterblande lægemidlet (som en vinduesvisker).
Again, slowly and gently rock the pen side to side 5 times to re-mix the medicine (like a windscreen wiper).
VIP IKKE.
DO NOT TILT.
VIP IKKE:
DO NOT TILT.
Vip inhalatoren, så mundstykket vender lidt nedad.
Tilt the inhaler so that the mouth-piece faces slightly downward.
Vip langsomt og forsigtigt pennen fra side til side 5 gange for at blande lægemidlet (som en vinduesvisker).
Slowly and gently rock the pen side to side 5 times to mix the medicine (like a windscreen wiper).
Vip pennen forsigtigt frem og tilbage nogle få gange for at blande medicinen
Gently rotate the pre-filled pen back and forth a few times to mix the medicine.
Vipdomet 12,5 mg/1.000 mg
Vipdomet 12.5 mg/1000 mg
Vipdomet 12,5 mg/1.000 mg filmovertrukne tabletter
Vipdomet 12.5 mg/1000 mg film-coated tablets
Vipdomet 12,5 mg/1.000 mg filmovertrukne tabletter (tabletter) er svagt gule, aflange (ca.
Vipdomet 12.5 mg/1000 mg film-coated tablets (tablets) are pale yellow, oblong (approximately
Vipdomet 12,5 mg/1.000 mg filmovertrukne tabletter alogliptin/metforminhydrochlorid
Vipdomet 12.5 mg/1000 mg film-coated tablets alogliptin/metformin hydrochloride
Vipdomet 12,5 mg/1.000 mg tabletter alogliptin/metforminhydrochlorid
Vipdomet 12.5 mg/1000 mg tablets alogliptin/metformin hydrochloride
Vipdomet 12,5 mg/850 mg filmovertrukne tabletter
Vipdomet 12.5 mg/850 mg film-coated tablets
Vipdomet 12,5 mg/850 mg filmovertrukne tabletter (tabletter) er lysegule, aflange (ca.
Vipdomet 12.5 mg/850 mg film-coated tablets (tablets) are light yellow, oblong (approximately
Vipdomet 12,5 mg/850 mg filmovertrukne tabletter alogliptin/metforminhydrochlorid
Vipdomet 12.5 mg/850 mg film-coated tablets alogliptin/metformin hydrochloride
Vipdomet 12,5 mg/850 mg filmovertrukne tabletter Vipdomet 12,5 mg/1.000 mg filmovertrukne tabletter Alogliptin/metforminhydrochlorid
Vipdomet 12.5 mg/850 mg film-coated tablets Vipdomet 12.5 mg/1000 mg film-coated tablets Alogliptin/Metformin hydrochloride
Vipdomet 12,5 mg/850 mg tabletter alogliptin/metforminhydrochlorid
Vipdomet 12.5 mg/850 mg tablets alogliptin/metformin hydrochloride
Vipdomet bør ikke anvendes under graviditet.
Vipdomet should not be used during pregnancy.
Vipdomet frarådes til patienter med moderat og svært nedsat nyrefunktion eller med dialysekrævende terminal nyresygdom (kreatininclearance < 60 ml/min) (se pkt.
Vipdomet is not recommended for use in patients with moderate and severe renal impairment and end-stage renal disease (creatinine clearance < 60 mL/min)(see section 4.3).
Vipdomet fås i blisterpakninger med 10, 14, 20, 28, 56, 60, 98, 112, 120, 180, 196, 196 (2x98 multipakning) eller 200 tabletter.
Vipdomet is available in blister packs containing 10, 14, 20, 28, 56, 60, 98, 112, 120, 180, 196, 196 (2x98 multipack) or 200 tablets.
Vipdomet indeholder to forskellige lægemidler, alogliptin og metformin, i én tablet:
Vipdomet contains two different medicines called alogliptin and metformin in one tablet:
Vipdomet påvirker ikke eller kun i ubetydelig grad evnen til at føre motorkøretøj eller betjene maskiner.
Vipdomet has no or negligible influence on the ability to drive and use machines.
Vipdomets farmakokinetik hos børn og unge under 18 år er ikke klarlagt.
The pharmacokinetics of Vipdomet in children and adolescents < 18 years old has not been established.
Vipidia 12,5 mg filmovertrukne tabletter (tabletter) er gule, ovale (ca.
Vipidia 12.5 mg film-coated tablets (tablets) are yellow, oval (approximately 9.1 mm long by
Vipidia 12,5 mg filmovertrukne tabletter alogliptin
Vipidia 12.5 mg film-coated tablets alogliptin
Vipidia 12,5 mg tabletter alogliptin
Vipidia 12.5 mg tablets alogliptin
Vipidia 25 mg filmovertrukne tabletter (tabletter) er svagt røde, ovale (ca.
Vipidia 25 mg film-coated tablets (tablets) are light red, oval (approximately 9.1 mm long by
Vipidia 25 mg filmovertrukne tabletter alogliptin
Vipidia 25 mg film-coated tablets alogliptin
Vipidia 25 mg filmovertrukne tabletter Vipidia 12,5 mg filmovertrukne tabletter Vipidia 6,25 mg filmovertrukne tabletter Alogliptin
Vipidia 25 mg film-coated tablets Vipidia 12.5 mg film-coated tablets Vipidia 6.25 mg film-coated tablets Alogliptin
Vipidia 25 mg tabletter alogliptin
Vipidia 25 mg tablets alogliptin
Vipidia 6,25 mg filmovertrukne tabletter (tabletter) er svagt pink, ovale (ca.
Vipidia 6.25 mg film-coated tablets (tablets) are light pink, oval (approximately 9.1 mm long by
Vipidia 6,25 mg filmovertrukne tabletter alogliptin
Vipidia 6.25 mg film-coated tablets alogliptin
Vipidia 6,25 mg tabletter alogliptin
Vipidia 6.25 mg tablets alogliptin
Vipidia indeholder det aktive stof alogliptin, som hører til en gruppe lægemidler, der kaldes orale antidiabetika (diabetesmedicin, der indtages gennem munden).
Vipidia contains the active substance alogliptin which belongs to a group of medicines called “oral anti-diabetics”.
Vipidia må ikke anvendes til patienter, som er overfølsomme (allergiske) over for de aktive stoffer eller andre af indholdsstofferne, eller som tidligere har haft en alvorlig allergisk reaktion over for en DPP4- hæmmer.
Vipidia must not be used in patients who are hypersensitive (allergic) to the active substances or any of the ingredients or who have had serious allergic reactions to any DPP 4 inhibitor.
vir
0.98
vir/ritonavir skal man i starten administrere 0,5 mg tacrolimus én gang om ugen.
navir administer 0.5 mg tacrolimus once every week.
Vira, der blev selekteret under disse betingelser, og som viste reduceret følsomhed over for darunavir (område: 23- 50-fold), indeholdt 2 til 4 aminosyresubstitutioner i proteasegenet.
Viruses selected in these conditions and showing decreased susceptibility to darunavir (range: 23-50-fold) harboured 2 to 4 amino acid substitutions in the protease gene.
Vira, der udtrykker T66I/A- substitutioner, bevarer følsomhed over for raltegravir, mens de fleste andre mønstre af elvitegravir- associerede substitutioner er forbundet med nedsat følsomhed over for raltegravir.
Viruses expressing the T66I/A substitutions maintain susceptibility to raltegravir, while most other patterns of elvitegravir-associated substitutions are associated with reduced susceptibility to raltegravir.
Vira, som har en mutation ved aminosyre 148 sammen med en eller flere andre raltegravir resistensmutationer, kan også have klinisk signifikant resistens over for dolutegravir.
Viruses harbouring a mutation at amino acid 148, along with one or more other raltegravir resistance mutations, may also have clinically significant resistance to dolutegravir.
VIRACEPT 250 filmovertrukne tabletter: Roche Pharma AG
VIRACEPT 250 mg film-coated tablets: Roche Pharma AG
VIRACEPT 250 mg filmovertrukne tabletter
VIRACEPT 250 mg film-coated tablets
Viracept 250 mg filmovertrukne tabletter Nelfinavir
Viracept 250 mg film-coated tablets Nelfinavir
VIRACEPT 250 mg filmovertrukne tabletter.
VIRACEPT 250 mg film-coated tablets.
VIRACEPT 50 mg/g oralt pulver
VIRACEPT 50 mg/g oral powder
Viracept 50 mg/g oralt pulver er et hvidt til off-white pulver.
Viracept 50 mg/g oral powder is a white to off-white powder.
Viracept 50 mg/g oralt pulver Nelfinavir
Viracept 50 mg/g oral powder Nelfinavir
VIRACEPT 50 mg/g oralt pulver.
VIRACEPT 50 mg/g oral powder.
VIRACEPT 50 mg/g oralt pulver:
VIRACEPT 50 mg/g oral powder
Viracept anvendes sammen med andre antiretrovirale lægemidler for at:
Viracept is used with other ‘anti-retroviral’ medicines to:
Viracept filmovertrukne tabletter leveres i plastikglas med børnesikrede plastiklåg.
Viracept film-coated tablets is supplied in plastic bottles with plastic child resistant lid.
Viracept indeholder det aktive indholdsstof nelfinavir, som er en proteasehæmmer.
Viracept contains a medicine called nelfinavir, which is a ‘protease inhibitor’.
Viracept kan forhindre orale præventionsmidler (p-piller) i at virke, så du bør bruge andre præventionsmetoder (som f.eks. kondom), mens du tager Viracept.
Viracept can stop oral contraceptives (the pill) from working, so you should use other contraception methods (such as condoms) while you are taking Viracept.
VIRACEPT suspensionen skal indtages med et måltid.
The VIRACEPT suspension should be taken with a meal.
Viracept-pulver kan indtages enten to eller tre gange daglig med et måltid.
Viracept powder can be taken either two or three times a day with a meal.
Viraene er valgt på grund af deres lave virulens (begrænsede evne til at fremkalde sygdommen).
The viruses have been selected because of their ‘low virulence’ (limited ability to cause the disease).
Viraene i den aktuelle formulering af Equilis Prequenza dyrkes i pattedyrceller i modsætning til dem i den oprindelige formulering, som blev dyrket i hønseæg
The viruses included in the current formulation of Equilis Prequenza are grown in mammalian cells, unlike those in the initial formulation, which were grown in hens’ eggs.
Viraene i den aktuelle formulering af Equilis Prequenza Te dyrkes i pattedyrceller i modsætning til dem i den oprindelige formulering, som blev dyrket i hønseæg.
The viruses included in the current formulation of Equilis Prequenza Te are grown in mammalian cells, unlike those in the initial formulation, which were grown in hens’ eggs.
Viraferon (3 MIE TIW)
Viraferon (3 MIU TIW)
Viraferon (3 MIE TIW) +
(3 MIU TIW) +
Viraferon (3 MIE TIW) +
Viraferon (3 MIU TIW) +
Viraferon (interferon alfa-2b) supplerer reaktionen fra kroppens immunsystem med henblik på at bekæmpe infektioner og alvorlige sygdomme.
Viraferon (interferon alfa-2b) modifies the response of the body's immune system to help fight infections and severe diseases.
Viraferon 1 MIE pulver
Viraferon 1 MIU powder
Viraferon 1 million IE/ml pulver og solvens til injektionsvæske interferon alfa-2b
Viraferon 1 million IU/ml powder and solvent for solution for injection interferon alfa-2b
Viraferon 1 million IE/ml pulver og solvens til injektionsvæske, opløsning
Viraferon 1 million IU/ml powder and solvent for solution for injection
Viraferon 1 million IE/ml pulver og solvens til injektionsvæske, opløsning
Viraferon, 1 million IU/ml powder and solvent for solution for injection
Viraferon 10 MIE injektionsvæske
Viraferon 10 MIU solution
Viraferon 10 MIE pulver
Viraferon 10 MIU powder
Viraferon 10 millioner IE/ml injektionsvæske interferon alfa-2b
Viraferon 10 million IU/ml solution for injection interferon alfa-2b
Viraferon 10 millioner IE/ml injektionsvæske, opløsning
Viraferon 10 million IU/ml solution for injection
Viraferon 10 millioner IE/ml injektionsvæske, opløsning
Viraferon, 10 million IU/ml solution for injection
Viraferon 10 millioner IE/ml pulver og solvens til injektionsvæske interferon alfa-2b
Viraferon 10 million IU/ml powder and solvent for solution for injection interferon alfa-2b
Viraferon 10 millioner IE/ml pulver og solvens til injektionsvæske, opløsning
Viraferon 10 million IU/ml powder and solvent for solution for injection
Viraferon 10 millioner IE/ml pulver og solvens til injektionsvæske, opløsning
Viraferon, 10 million IU/ml powder and solvent for solution for injection
Viraferon 18 MIE injektionsvæske
Viraferon 18 MIU solution
Viraferon 18 MIE pen
Viraferon 18 MIU pen
Viraferon 18 millioner IE injektionsvæske flerdosispen interferon alfa-2b
Viraferon 18 million IU solution for injection multidose pen interferon alfa-2b
Viraferon 18 millioner IE injektionsvæske, opløsning, flerdosispen
Viraferon 18 million IU solution for injection, multidose pen
Viraferon 18 millioner IE injektionsvæske, opløsning, flerdosispen
Viraferon, 18 million IU solution for injection, multidose pen
Viraferon 18 millioner IE/3 ml injektionsvæske interferon alfa-2b
Viraferon 18 million IU/3 ml solution for injection interferon alfa-2b
Viraferon 18 millioner IE/3 ml injektionsvæske, opløsning
Viraferon 18 million IU/3 ml solution for injection
Viraferon 18 millioner IE/3 ml injektionsvæske, opløsning
Viraferon, 18 million IU/3 ml solution for injection
Viraferon 25 MIE injektionsvæske
Viraferon 25 MIU solution